Aeterna Zentaris (AEZS) is up 8.5% premarket after announcing favorable results for a Phase 3 study related to its AEZS-130 drug for treating adult growth hormone deficiency. The company now plans to consult with the FDA regarding the submission of a new drug application (NDA).
Sent to 3,294 people who get email alerts on AEZS.
Get email alerts on AEZS »
Want to be faster and smarter on all your stocks?
Upgrade all your basic real-time alerts to PRO Alerts, for $30.